CEP89

Across TCGA pan-cancer cohorts, CEP89 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CEP89’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CEP89 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CEP89 is over-expressed in tumor, although a few such as LUAD and PDAC show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where CEP89 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEP89 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.477	.005	6	view →
CCRCC	All	II,III,IV	+0.239	.006	6	view →
LUAD	Female	All	−0.321	<.001	5	view →
PDAC	Male	II,III,IV	−0.927	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CEP89–HNSC

Open the HNSC breakdown →